Eye Care Benefits of Anti-Aging Compound Capsules in Healthy Adults (Eye Care)
Exploring the Eye Care Benefits of Anti-aging Compound Capsules
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.
The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.
This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.
The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.
The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Taichung, Taiwan
- Department of Optometry, Chung Shan Medical University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent.
Spherical equivalent refractive error less than 700 diopters of myopia (i.e., < -7.00 D).
Exclusion Criteria:
- Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators.
History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).
Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.
Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:
Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Anti-Aging Compound Capsules
Participants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks.
Participants will take 2 capsules twice daily (total daily dose 2,200 mg).
|
Participants will consume anti-aging compound capsules twice daily for 4 weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Total daily intake is 2,200 mg.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Ocular Surface Disease Index (OSDI) Score
Tijdsspanne: baseline / week2 / week4
|
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire.
The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function.
Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
|
baseline / week2 / week4
|
|
Change in Distance Visual Acuity (DVA, logMAR)
Tijdsspanne: baseline / week2 / week4
|
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Near Visual Acuity (NVA)
Tijdsspanne: baseline / week2 / week4
|
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Accommodative Response
Tijdsspanne: baseline / week2 / week4
|
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead.
Measurements will be conducted at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Accommodative Facility (cycles per minute)
Tijdsspanne: baseline / week2 / week4
|
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets.
Results will be recorded as cycles per minute (CPM).
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Tear Film Break-Up Time (TBUT)
Tijdsspanne: baseline / week2 / week4
|
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800).
Assessments will be conducted at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Macular Pigment Optical Density (MPOD)
Tijdsspanne: baseline / week2 / week4
|
Macular pigment optical density will be measured using a macular pigment optical density analyzer.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
|
Change in Photostress Recovery Time
Tijdsspanne: baseline / week2 / week4
|
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus.
Assessments will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Intraocular Pressure (IOP)
Tijdsspanne: baseline / week2 / week4
|
Intraocular pressure will be measured using non-contact tonometry.
Measurements will be performed at baseline, Week 2, and Week 4.
|
baseline / week2 / week4
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Lin, associated professor, Institute of Medical Research, Chung Shan Medical University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CS1-25234
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .